PortfoliosLab logo
GeneDx Holdings Corp. (WGS)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

IPO Date

Nov 4, 2020

Highlights

Market Cap

$1.93B

EPS (TTM)

-$1.39

Total Revenue (TTM)

$330.14M

Gross Profit (TTM)

$211.05M

EBITDA (TTM)

-$20.55M

Year Range

$19.49 - $117.75

Target Price

$93.32

Short %

25.27%

Short Ratio

2.95

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Performance

Performance Chart


Loading data...

S&P 500

Returns By Period

GeneDx Holdings Corp. (WGS) returned -12.40% year-to-date (YTD) and 236.82% over the past 12 months.


WGS

YTD

-12.40%

1M

-30.51%

6M

-6.58%

1Y

236.82%

3Y*

3.50%

5Y*

N/A

10Y*

N/A

^GSPC (Benchmark)

YTD

-0.67%

1M

10.48%

6M

-1.79%

1Y

10.08%

3Y*

13.71%

5Y*

14.60%

10Y*

10.64%

*Annualized

Monthly Returns

The table below presents the monthly returns of WGS, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2025-2.62%37.41%-13.89%-24.52%0.72%-12.40%
202440.00%111.69%12.02%86.97%14.88%33.30%25.17%-2.38%32.87%92.48%-4.04%-1.95%2,694.91%
202360.98%17.65%-27.00%-24.93%-16.83%-20.74%24.33%-39.95%-18.20%-48.90%-5.91%57.14%-68.43%
2022-23.32%2.05%-12.03%-29.97%-5.12%-38.24%28.57%-37.04%-13.92%17.31%-59.81%-36.23%-94.08%
202113.32%59.95%-25.59%-9.00%-6.57%10.66%-19.49%-15.78%-20.11%6.32%-17.35%-33.13%-59.60%
20204.54%7.76%12.65%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

With an overall rank of 94, WGS is among the top 6% of stocks on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.


The Risk-Adjusted Performance Rank of WGS is 9494
Overall Rank
The Sharpe Ratio Rank of WGS is 9696
Sharpe Ratio Rank
The Sortino Ratio Rank of WGS is 9393
Sortino Ratio Rank
The Omega Ratio Rank of WGS is 9292
Omega Ratio Rank
The Calmar Ratio Rank of WGS is 9494
Calmar Ratio Rank
The Martin Ratio Rank of WGS is 9696
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for GeneDx Holdings Corp. (WGS) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


The Sharpe ratio helps investors understand how much return they're getting for the level of risk taken. A higher Sharpe ratio indicates better risk-adjusted performance, meaning more reward for each unit of risk.

GeneDx Holdings Corp. Sharpe ratios as of May 23, 2025 (values are recalculated daily):

  • 1-Year: 2.13
  • All Time: -0.26

These values reflect how efficiently the investment has delivered returns relative to its volatility over different time periods. All figures are annualized and based on daily total returns (including price changes and dividends).

The chart below shows the rolling Sharpe ratio of GeneDx Holdings Corp. compared to the selected benchmark. This view highlights how the investment's risk-adjusted performance has changed over time. For deeper analysis or to customize the calculation, use the Sharpe ratio tool.


Loading data...

Dividends

Dividend History


GeneDx Holdings Corp. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


Loading data...

Worst Drawdowns

The table below displays the maximum drawdowns of the GeneDx Holdings Corp.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the GeneDx Holdings Corp. was 99.85%, occurring on Nov 13, 2023. The portfolio has not yet recovered.

The current GeneDx Holdings Corp. drawdown is 92.09%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-99.85%Feb 16, 2021692Nov 13, 2023
-7.25%Dec 28, 20205Jan 4, 20216Jan 12, 202111
-4.43%Jan 14, 20213Jan 19, 20213Jan 22, 20216
-4.37%Dec 3, 20201Dec 3, 20207Dec 14, 20208
-4.01%Jan 27, 20211Jan 27, 20214Feb 2, 20215

Volatility

Volatility Chart

The chart below shows the rolling one-month volatility.


Loading data...

Financials

Financial Performance

The chart below illustrates the trends in the financial health of GeneDx Holdings Corp. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.


Annual
Quarterly

0.0

Earnings Per Share

The chart presents the Earnings Per Share (EPS) performance of GeneDx Holdings Corp., comparing actual results with analytics estimates. The company has exceeded analyst expectations for EPS in the past quarter, achieving a 140.8% positive surprise.


-3.00-2.00-1.000.001.002021AprilJulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober2025
0.27
-0.67
Actual
Estimate

Valuation

The Valuation section provides an overview of how GeneDx Holdings Corp. is priced in the market compared to other companies in the Health Information Services industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.


PS Ratio

This chart shows the Price-to-Sales (P/S) ratio for WGS relative to other companies in the Health Information Services industry. Currently, WGS has a P/S ratio of 5.9. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.

PB Ratio

The chart illustrates the Price-to-Book (P/B) ratio for WGS in comparison with other companies in the Health Information Services industry. Currently, WGS has a P/B value of 7.5. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items